Symeres, a European drug discovery contract research organization (CRO) and contract development and manufacturing organization (CDMO), has acquired Organix Inc., a U.S.-based specialized organic chemistry services provider with a focus on lipids.

Organix, based in the Boston, MA area, is a provider of high-quality organic chemistry services dedicated to the discovery and preclinical stage of the drug discovery value chain. Its revenue is mainly generated from the sale of specialized and complex organic chemistry research services to biopharma clients. Organix is currently generating over $10 million of revenues, from a base of 45 employees.

Organix brings a presence in the U.S. market, where Symeres generates nearly 50% of its revenues. Organix also broadens Symeres’ drug discovery offering into the fast-growing lipids market, addressing mRNA therapeutics and vaccines. Organix’s client list includes some of the world’s leading biopharma companies, including many based in the Boston biopharma community.

Symeres is one of the largest European small molecule CRO and CDMOs, providing R&D services from preclinical drug discovery to Phase I and II clinical stage drug development and manufacturing, to major pharmaceutical and biotechnology companies around the globe. Its services include integrated small molecule optimization efforts, complex synthetic chemistry, route scouting and API synthesis up to GMP production, solid state chemistry and ADME-Tox services.

Symeres, headquartered in the Netherlands, employs over 500 people and operates in the Netherlands, the Czech Republic and Nordics, along with an existing business development office in the Boston area. Over several decades, the company has enjoyed a strong growth trajectory, with revenues rising organically at a double-digit rate per annum, further complemented by strategic M&A.

“We are proud to become part of the Symeres family where we have found a trusted partner that shares our values and business philosophy of strong customer focus,” said Anu Mahadevan, CEO of Organix. “The added expertise that the deal brings will allow Organix to better serve our clients by providing additional access to state-of-the-art cGMP services. We look forward to being a part of this innovative and science-driven organization.”

Eelco Ebbers, co-founder and CEO of Symeres, said, “We are pleased to welcome Organix into the Symeres Group. Organix is widely known as a highly innovative and expert organic chemistry services provider that solves complex projects for top tier clients globally. Joining forces represents a fantastic opportunity for Symeres to expand our drug discovery capability offering and will provide an exceptional foothold into the U.S. market.”